Phase Ib Evaluation of the Safety and Tolerability and Effect on Midazolam Metabolism of the Administration of Multiple Rising Doses of BI 730357 to Healthy Volunteers.

Trial Profile

Phase Ib Evaluation of the Safety and Tolerability and Effect on Midazolam Metabolism of the Administration of Multiple Rising Doses of BI 730357 to Healthy Volunteers.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs BI 730357 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 13 Oct 2017 Planned number of patients changed from 240 to 60.
    • 19 Sep 2017 Planned End Date changed from 12 Feb 2019 to 20 Apr 2019.
    • 19 Sep 2017 Planned primary completion date changed from 2 Nov 2018 to 14 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top